samedan logo
 
 
 
spacer
home > ebr > spring 2003 > partners with vision - a discussion on the future of pharma
PUBLICATIONS
European Biopharmaceutical Review

Partners With Vision - A Discussion on the Future of Pharma

No single person can accurately predict the future of the pharmaceutical industry. Unprecedented competition, a weak economy, pricing pressures, public scrutiny and ever-increasing regulation characterise the current environment. In the face of these business challenges, some organisations are achieving exciting innovations while others' efforts have been stifled. Many companies are surmounting these obstacles and forging new partnerships, providing significant scientific insights to the medical community and producing lifesaving treatments to patients. However, many more companies are struggling to meet the industry's unmet challenges. While no road map exists to guide pharmaceutical companies through today's market pressures or to help them anticipate tomorrow's challenges, a vision of how the pharmaceutical industry will develop could provide benefits to the sector.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By William Powlett Smith, Audit Partner and Leader of UK Health Sciences at Ernst & Young LLP

William Powlett Smith is Audit Partner and Leader of UK Health Sciences at Ernst & Young LLP. William is well known for his extensive work with biotechnology and pharmaceutical businesses and his strong international connections, particularly with Ernst & Young's offices on the east and west coasts of the USA and in Germany.

He is now the Partner responsible for the UK firm's Health Sciences practice. Until October 1999 William was a member of the BIA's Board of Directors, and of the BIA Sub-Committee responsible for drafting the BIA's Code of Best Practice. He was a contributor to, and Co-ordinating Partner for, the production of Ernst & Young's 1998, 1999 and 2000 European Life Sciences Reports.

spacer
William Powlett Smith
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Huge boom in Korean Pharma reported at CPhI Korea

Amsterdam, 19th September 2019: The recently-closed CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – has seen a surge in growth across domestic and international pharma companies, as well as a sizable rise in overall attendees. As reported earlier this year in the provisional findings of the CPhI Pharma Index[1], Korea has seen a rapid growth in its international reputation (seeing its ‘overall competitiveness’ rise 14% in the last two years), which is now translating into a sizable growth in the market and at the event.
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement